Condor Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Condor Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Sell	3,503 -2,958	-46%	-$1.31M	0.13%	98
2026 Q1	$2.89M	Sell	6,461 -26	-0.4%	-$12.1K	0.24%	83
2025 Q4	$2.94M	Sell	6,487 -20	-0.3%	-$8.62K	0.24%	84
2025 Q3	$2.55M	Buy	6,507 +5	+0.1%	+$2.09K	0.21%	90
2025 Q2	$2.89M	Sell	6,502 -26	-0.4%	-$12K	0.25%	86
2025 Q1	$3.16M	Hold	6,528	–	–	0.29%	77
2024 Q4	$2.63M	Sell	6,528 -30	-0.5%	-$13.9K	0.23%	91
2024 Q3	$3.05M	Sell	6,558 -41	-0.6%	-$19.7K	0.27%	78
2024 Q2	$3.09M	Sell	6,599 -281	-4%	-$122K	0.3%	78
2024 Q1	$2.88M	Sell	6,880 -143	-2%	-$60.5K	0.28%	83
2023 Q4	$2.86M	Sell	7,023 -75	-1%	-$27.7K	0.31%	80
2023 Q3	$2.47M	Buy	7,098 +7	+0.1%	+$2.45K	0.3%	73
2023 Q2	$2.5M	Sell	7,091 -135	-2%	-$45.5K	0.3%	72
2023 Q1	$2.28M	Buy	7,226 +4	+0.1%	+$1.2K	0.29%	77
2022 Q4	$2.09M	Buy	7,222 +36	+0.5%	+$11K	0.26%	87
2022 Q3	$2.08M	Sell	7,186 -234	-3%	-$67.3K	0.27%	84
2022 Q2	$2.09M	Buy	7,420 +131	+2%	+$35.1K	0.27%	82
2022 Q1	$1.9M	Buy	7,289 +3,251	+81%	+$772K	0.21%	101
2021 Q4	$887K	Sell	4,038 -3,433	-46%	-$668K	0.1%	138
2021 Q3	$1.35M	Buy	7,471 +219	+3%	+$42.8K	0.14%	126
2021 Q2	$1.46M	Sell	7,252 -21	-0.3%	-$4.39K	0.16%	118
2021 Q1	$1.56M	Buy	+7,273	New	+$1.6M	0.19%	107

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Condor Capital Management's VRTX Position: Q2 2026 in Review

Condor Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 46% in Q2 2026, selling an estimated $1.31M and leaving 3,503 shares worth $1.74M. The position accounts for 0.13% of the portfolio, ranked #98.

Condor Capital Management first reported a position in VRTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $3.16M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Condor Capital Management held 3,503 shares of Vertex Pharmaceuticals worth $1.74M as of Q2 2026.
Condor Capital Management sold 2,958 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.31M.
Vertex Pharmaceuticals made up 0.13% of Condor Capital Management's portfolio in Q2 2026, its #98 holding.
Condor Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
Condor Capital Management's Vertex Pharmaceuticals position peaked at $3.16M in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Condor Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.